This article covers what the actual evidence supports for each route, and why "bypasses the skin barrier" turns out to be a much smaller part of the real comparison than it first appears
A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder
For the skin-and-connective-tissue-quality use case KLOW was built for, the research default is monotherapy the blend already addresses inflammation, perfusion, migration, and remodeling
For the global metabolite profiling in serum, the metabolites in 10 L of serum were extracted by the 390 L of pre-chilled 82% MeOH (80 C) followed by 15 min incubation at 80 C
Why the IV-to-subcutaneous gap is not a technicality For many peptides, moving from IV to subcutaneous changes the pharmacokinetics modestly a slower rise, a lower peak, decent bioavailability